A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2019-01-31
Target enrollment:
Participant gender:
Summary
Antiangiogenesis therapy plays an important role in cancer treatment. Apatinib showed good
safety and efficacy as third-line therapy for advanced gastric cancer.We conducted this trial
to investigate the safety and efficacy of apatinib combined with S1 after failure of
first-line chemotherapy in advanced gastric cancer or gastroesophageal junction carcinoma
patients.